Wednesday, February 1, 2017

Selecting Therapy in CLL

The CLL landscape continues to change very quickly.  I have previously written about picking a first line therapy, but my post from 2013 has become quickly outdated.

I recently had the opportunity to participate with a group called "Clinical Care Options" on a decision support tool that allows you to plug in a variety of variables that are central to picking out a treatment regimen and then seeing what therapy would be selected by a handful of experts.

To use the tool, you have to register for an account - but I thought it would be worth it for a number of patients who are at the point of picking out a particular therapy.

Here is a link to the tool

I also serve on the CLL Steering Committee for Medscape.  We have recently conducted several taped interviews discussing how to pick therapy in both the front line and relapsed / refractory setting.  Here again, you need to sign up for an account - but worth it if you want more color commentary regarding the tool outlined above.

Here is the link for the frontline video with me and Steve Coutre

Here is the link for the the relapsed / refractory video with Stephen Schuster, Matthew Davids and Amy Goodrich

I would like to predict that these will remain relevant tools for the foreseeable future but I am happy to report that they will only be valuable for another 12-24 months before the world changes again.

I tried to embed these tools directly on the blog but unfortunately was not able to do so.  I hope you find them helpful.

Thanks for reading / viewing / tooling.

Wednesday, December 7, 2016

ASH 2016 with Patient Power

Just back from ASH 2016.  Plenty of interesting things to discuss.  I did a sit down visit with Andrew Schorr of PatientPower where we filmed this 45 minute discussion of relevant topics in CLL.  We were joined by some great docs from MD Anderson and Cambridge Hospital in England.

I am dismayed about my inability to get much blogging done recently.  The good news is that the research side of my career has been soaking up all my free time, but it has left me little time for the blog posts which take me several hours each.

I have a few things I hope to put up if I can get around to it, but thought this video might be useful to folks.  We talk about the role of molecular testing, treatment goals, ibrutinib dosing and other relevant new findings.  I hope you enjoy the video.

As always, you can leave a comment by clicking on the post title and then scrolling to the bottom.  Thanks for watching

Thursday, May 12, 2016

The Improvisational Oncologist

I have been a big fan of Sid Mukherjee ever since we were om training together.   I was a mere intern and he was a Jr. Resident but it is always fun to be in the presence of somebody who is really smart and really humble about it.

He went on to write, "The Emperor of all Maladies" which won the Pulitzer Prize and documents the history of cancer treatment.  If you haven't read it, I highly recommend you read it or watch the six hour documentary that Ken Burns made out of it for PBS.

Sid wrote an article for the New York Times Magazine posted this weekend called "The Improvisational Oncologist."  It is an informative read that describes some of the new medical adventures we have to take with our patients.  If you haven't read it, I would encourage you to do so.